Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

Open access
Woolhouse, Ian, Bishop, Lesley, Darlison, Liz, De Fonseka, Duneesha, Edey, Anthony, Edwards, John, Faivre-Finn, Corinne, Fennell, Dean A, Holmes, Steve, Kerr, Keith M, Nakas, Apostolos, Peel, Tim, Rahman, Najib M, Slade, Mark, Steele, Jeremy, Tsim, Selina, Maskell, Nick A · 2018 · Thorax

Abstract

Section 3: Clinical features which predict the presence of mesothelioma Recommendations Section 4: Staging systems Recommendation Section 5: Imaging modalities for diagnosing and staging Recommendations Section 6: Pathological diagnosis Recommendations

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thoraxjnl-2017-211321

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 232

  1. 10.1136/thx.2007.087619 · DOI · Paper page
  2. Beckett, 2015, Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales, Lung Cancer, 88, 344, 10.1016/j.lungcan.2015.03.005 · DOI
  3. 10.1136/thx.52.6.507 · DOI · Paper page
  4. Aguilar-Madrid, 2010, Case-control study of pleural mesothelioma in workers with social security in Mexico, Am J Ind Med, 53, 241, 10.1002/ajim.20780 · DOI
  5. 10.1023/A:1007691003600 · DOI · Paper page
  6. Cigognetti, 2015, BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations, Mod Pathol, 28, 1043, 10.1038/modpathol.2015.65 · DOI · Paper page
  7. 10.1159/000321370 · DOI
  8. 10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5 · doi:10.1002/1097-0142(19861001)58:7<1540::aid-cncr2820580727>3.0.co;2-5
  9. Rusch, 2016, The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma, J Thorac Oncol, 11, 2112, 10.1016/j.jtho.2016.09.124 · DOI · Paper page
  10. Sugarbaker, 1993, Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma, J Clin Oncol, 11, 1172, 10.1200/JCO.1993.11.6.1172 · DOI · Paper page
  11. 10.1136/thoraxjnl-2014-206054 · DOI
  12. Salonen, 1986, Computed tomography of pleural lesions with special reference to the mediastinal pleura, Acta Radiol Diagn, 27, 527, 10.1177/028418518602700507 · doi:10.1177/028418518602700507
  13. Seely, 2009, Malignant pleural mesothelioma: computed tomography and correlation with histology, Eur J Radiol, 70, 485, 10.1016/j.ejrad.2008.02.004 · DOI
  14. Okten, 2006, Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos, Clin Imaging, 30, 177, 10.1016/j.clinimag.2005.12.027 · doi:10.1016/j.clinimag.2005.12.027
  15. 10.1080/028418501127347070 · DOI
  16. 10.1016/S0720-048X(01)00426-0 · DOI · Paper page
  17. 10.1378/chest.118.3.604 · DOI
  18. 10.2214/ajr.154.3.2106209 · DOI · Paper page
  19. Yilmaz, 2005, CT in differential diagnosis of benign and malignant pleural disease, Monaldi Arch Chest Dis, 63, 17, 10.4081/monaldi.2005.653 · doi:10.4081/monaldi.2005.653
  20. 10.1136/thx.2008.100545 · doi:10.1136/thx.2008.100545
  21. Elboga, 2012, The role of FDG PET-CT in differential diagnosis of pleural pathologies, Rev Esp Med Nucl Imagen Mol, 31, 187
  22. 10.1378/chest.14-0820 · DOI
  23. 10.1378/chest.114.3.713 · DOI · Paper page
  24. Abe, 2012, Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma, Oncol Rep, 27, 333
  25. 10.1097/JTO.0b013e3181c0a7ff · DOI
  26. Treglia, 2014, Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis, Acad Radiol, 21, 11, 10.1016/j.acra.2013.09.015 · doi:10.1016/j.acra.2013.09.015
  27. 10.1148/radiol.12110872 · DOI
  28. Boraschi, 1999, Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases, Scand J Work Environ Health, 25, 18, 10.5271/sjweh.378 · doi:10.5271/sjweh.378
  29. Revelli M , Chiesa F , Del Prato A , et al . Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease. Br J Radiol 2016. doi:10.1259/bjr.20160289. [Epub ahead of print 29 Jun 2016]. · doi:10.1259/bjr.20160289
  30. 10.2214/AJR.09.3519 · DOI
  31. Coolen, 2015, Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging, Radiology, 274, 576, 10.1148/radiol.14132111 · doi:10.1148/radiol.14132111
  32. 10.1378/chest.129.6.1570 · DOI
  33. 10.3816/CLC.2009.n.033 · DOI
  34. 10.1097/RLI.0b013e3181817b3d · DOI
  35. 10.1016/S1010-7940(03)00609-2 · DOI
  36. 10.1016/S0003-4975(03)00010-9 · doi:10.1016/s0003-4975(03)00010-9
  37. 10.2214/ajr.172.4.10587144 · DOI · Paper page
  38. Niccoli-Asabella, 2013, 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up), Clin Imaging, 37, 1098, 10.1016/j.clinimag.2013.06.009 · doi:10.1016/j.clinimag.2013.06.009
  39. 10.1016/S0169-5002(98)00083-X · doi:10.1016/s0169-5002(98)00083-x
  40. 10.2214/ajr.159.5.1414807 · doi:10.2214/ajr.159.5.1414807
  41. Erasmus, 2005, Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications, J Thorac Cardiovasc Surg, 129, 1364, 10.1016/j.jtcvs.2004.10.034 · DOI · Paper page
  42. Fiore, 2006, Imaging before and after multimodal treatment for malignant pleural mesothelioma, Radiol Med, 111, 355, 10.1007/s11547-006-0034-3 · doi:10.1007/s11547-006-0034-3
  43. 10.1016/S0022-5223(03)00207-1 · DOI · Paper page
  44. Frauenfelder, 2015, Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma, J Comput Assist Tomogr, 39, 160, 10.1097/RCT.0000000000000174 · doi:10.1097/rct.0000000000000174
  45. 10.7785/tcrt.2012.500245 · doi:10.7785/tcrt.2012.500245
  46. Martini, 2016, Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma, Lung Cancer, 94, 40, 10.1016/j.lungcan.2016.01.017 · doi:10.1016/j.lungcan.2016.01.017
  47. Pinelli, 2015, Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?, Respiration, 89, 558, 10.1159/000381922 · doi:10.1159/000381922
  48. 10.1510/icvts.2010.255893 · DOI
  49. 10.1510/icvts.2010.255901 · doi:10.1510/icvts.2010.255901
  50. 10.1016/j.jtho.2015.11.005 · DOI · Paper page
  51. 10.5858/arpa.2012-0214-OA · DOI · Paper page
  52. 10.1309/AJCPT94JVWIHBKRD · DOI
  53. Hida, 2015, Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue, Cancer Sci, 106, 1635, 10.1111/cas.12769 · DOI
  54. Walters, 2011, Biopsy techniques for the diagnosis of mesothelioma, Recent Results Cancer Res, 189, 45, 10.1007/978-3-642-10862-4_4 · doi:10.1007/978-3-642-10862-4_4
  55. 10.1097/PAT.0b013e32835bc848 · DOI
  56. Cui A , Jin XG , Zhai K , et al . Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 2014;4:e004145. · DOI
  57. Hu, 2014, Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis, Clin Chim Acta, 433, 44, 10.1016/j.cca.2014.02.024 · DOI
  58. Lin, 2014, Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis, Int J Clin Exp Med, 7, 1289
  59. Kirschner, 2015, Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis, Br J Cancer, 113, 963, 10.1038/bjc.2015.286 · DOI
  60. 10.1158/1078-0432.CCR-10-1929 · DOI
  61. Creaney, 2013, Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma, Lung Cancer, 82, 491, 10.1016/j.lungcan.2013.09.016 · DOI
  62. 10.1155/2012/430689 · DOI
  63. 10.1038/bjc.2013.815 · DOI
  64. 10.1164/rccm.200807-1125OC · DOI
  65. Hirayama, 2011, Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma, Respir Med, 105, 137, 10.1016/j.rmed.2010.10.010 · DOI
  66. 10.1097/JTO.0b013e3182272294 · DOI
  67. 10.1097/JTO.0b013e31822a3740 · DOI
  68. 10.1016/j.lungcan.2011.06.007 · DOI
  69. 10.1097/JTO.0b013e31823f45c1 · DOI
  70. Thylén, 2001, Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma, Cancer, 92, 1224, 10.1002/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U · DOI
  71. 10.1200/JCO.2009.26.9944 · DOI
  72. 10.1186/1756-9966-32-7 · DOI
  73. Hooper, 2015, The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication, Br J Cancer, 112, 1175, 10.1038/bjc.2015.62 · DOI
  74. 10.1164/rccm.200802-258OC · DOI
  75. Filiberti, 2014, Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos, Oncology, 86, 33, 10.1159/000355687 · DOI
  76. Bayram, 2014, Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos, Lung, 192, 197, 10.1007/s00408-013-9526-9 · DOI
  77. 10.1007/s00204-010-0580-2 · DOI
  78. 10.1158/1055-9965.EPI-08-0422 · doi:10.1158/1055-9965.epi-08-0422
  79. 10.1200/JCO.2007.12.5294 · doi:10.1200/jco.2007.12.5294
  80. Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145 · DOI · Paper page
  81. 10.1200/JCO.2005.07.050 · DOI
  82. 10.1038/bjc.2013.504 · DOI
  83. 10.1136/thorax.55.9.731 · DOI · Paper page
  84. 10.1378/chest.113.3.723 · DOI · Paper page
  85. 10.1136/thoraxjnl-2014-205285 · DOI · Paper page
  86. Brims, 2016, A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis, J Thorac Oncol, 11, 573, 10.1016/j.jtho.2015.12.108 · DOI · Paper page
  87. Gemba, 2013, Treatment and survival analyses of malignant mesothelioma in Japan, Acta Oncol, 52, 803, 10.3109/0284186X.2012.709948 · DOI
  88. 10.1097/JTO.0b013e3181f1cf2b · DOI · Paper page
  89. 10.1016/j.athoracsur.2014.04.040 · DOI
  90. 10.1016/S0140-6736(14)60418-9 · DOI · Paper page
  91. 10.1001/jama.2012.5535 · DOI · Paper page
  92. 10.1136/thoraxjnl-2012-203043 · doi:10.1136/thoraxjnl-2012-203043
  93. 10.1007/s00408-011-9283-6 · DOI
  94. 10.1111/j.1440-1843.2005.00763.x · doi:10.1111/j.1440-1843.2005.00763.x
  95. Brancatisano, 1991, Pleurectomy for mesothelioma, Med J Aust, 154, 455, 10.5694/j.1326-5377.1991.tb121175.x · doi:10.5694/j.1326-5377.1991.tb121175.x
  96. 10.1186/1749-8090-5-27 · doi:10.1186/1749-8090-5-27
  97. Basso, 2012, Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results, Anticancer Res, 32, 5131
  98. 10.1016/j.lungcan.2009.02.023 · DOI
  99. 10.1097/JTO.0b013e3182208e3f · DOI · Paper page
  100. 10.1016/S1470-2045(11)70149-8 · DOI · Paper page
  101. 10.1016/j.athoracsur.2012.05.102 · doi:10.1016/j.athoracsur.2012.05.102
  102. Bölükbas, 2012, Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma, J Thorac Oncol, 7, 900, 10.1097/JTO.0b013e31824de2dc · doi:10.1097/jto.0b013e31824de2dc
  103. Burkholder, 2015, Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma, Ann Thorac Surg, 99, 1775, 10.1016/j.athoracsur.2015.01.058 · DOI
  104. 10.1177/0218492312454017 · DOI
  105. 10.1097/JTO.0b013e3181ed0489 · DOI
  106. Cao, 2012, Systematic review of trimodality therapy for patients with malignant pleural mesothelioma, Ann Cardiothorac Surg, 1, 428
  107. 10.1016/j.lungcan.2013.04.024 · doi:10.1016/j.lungcan.2013.04.024
  108. 10.1016/j.lungcan.2013.11.026 · DOI · Paper page
  109. Lim, 2016, A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study, Lung Cancer, 91, S71, 10.1016/S0169-5002(16)30212-4 · doi:10.1016/s0169-5002(16)30212-4
  110. 10.1097/JTO.0b013e318286c72b · doi:10.1097/jto.0b013e318286c72b
  111. 10.1016/j.athoracsur.2014.09.056 · DOI · Paper page
  112. 10.1200/JCO.20005.14.589 · DOI · Paper page
  113. 10.1016/S0140-6736(08)60727-8 · DOI · Paper page
  114. Mordant, 2008, MVP and vinorelbine for malignant pleural mesothelioma, Lancet, 372, 629, 10.1016/S0140-6736(08)61273-8 · doi:10.1016/s0140-6736(08)61273-8
  115. Zalcman, 2015, Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial, J of Clinical Oncology, 33, 7500, 10.1200/jco.2015.33.15_suppl.7500 · DOI
  116. 10.1097/JTO.0b013e31817c73d6 · DOI · Paper page
  117. Buikhuisen, 2015, Second line therapy in malignant pleural mesothelioma: A systematic review, Lung Cancer, 89, 223, 10.1016/j.lungcan.2015.06.018 · DOI
  118. 10.1200/JCO.2006.09.9887 · DOI · Paper page
  119. 10.1016/S1470-2045(15)70056-2 · DOI · Paper page
  120. Thapa, 2017, The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma, J Thorac Oncol, 12, 850, 10.1016/j.jtho.2017.02.013 · DOI
  121. Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, 18, 623, 10.1016/S1470-2045(17)30169-9 · DOI · Paper page
  122. 10.1378/chest.108.3.754 · DOI · Paper page
  123. 10.1038/sj.bjc.6601957 · DOI · Paper page
  124. 10.1016/j.radonc.2007.05.022 · DOI · Paper page
  125. 10.1016/S1470-2045(16)30095-X · DOI · Paper page
  126. 10.1016/j.lungcan.2009.06.014 · DOI
  127. Bayman N , Ardron D , Ashcroft L , et al . Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ Open 2016;6:e010589. · DOI
  128. de Perrot, 2016, Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma, J Thorac Cardiovasc Surg, 151, 468, 10.1016/j.jtcvs.2015.09.129 · DOI
  129. 10.1183/09031936.96.09122565 · DOI
  130. 10.1016/j.ijrobp.2014.05.032 · doi:10.1016/j.ijrobp.2014.05.032
  131. 10.1016/j.ijrobp.2006.03.012 · DOI · Paper page
  132. 10.1016/j.ijrobp.2007.02.047 · DOI
  133. Bille, 2012, Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals, Gen Thorac Cardiovasc Surg, 60, 289, 10.1007/s11748-011-0915-9 · DOI
  134. 10.1016/j.lungcan.2009.08.019 · DOI
  135. 10.1097/01243894-200605000-00004 · doi:10.1097/01243894-200605000-00004
  136. 10.1016/j.radonc.2009.03.011 · doi:10.1016/j.radonc.2009.03.011
  137. 10.1097/JTO.0b013e318031d05c · DOI
  138. Minatel, 2012, Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung, J Thorac Oncol, 7, 1862, 10.1097/JTO.0b013e318272601f · doi:10.1097/jto.0b013e318272601f
  139. 10.1016/j.lungcan.2013.10.013 · DOI
  140. 10.1016/j.ijrobp.2007.03.011 · DOI
  141. Pagan, 2006, 5-year prospective results of trimodality treatment for malignant pleural mesothelioma, J Cardiovasc Surg, 47, 595
  142. 10.1067/mtc.2001.116560 · DOI · Paper page
  143. Tonoli, 2011, Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series, Radiother Oncol, 101, 311, 10.1016/j.radonc.2011.09.025 · DOI
  144. 10.1183/09031936.00039510 · DOI · Paper page
  145. 10.1093/annonc/mdm093 · DOI · Paper page
  146. 10.1016/S1470-2045(15)00208-9 · DOI · Paper page
  147. 10.1200/JCO.2016.67.2675 · DOI · Paper page
  148. 10.1016/S0936-6555(05)80582-5 · DOI
  149. 10.1097/JTO.0000000000000499 · DOI
  150. 10.1111/j.1440-1673.1994.tb00177.x · DOI
  151. 10.1016/S0360-3016(98)00409-X · DOI
  152. 10.1016/j.ejca.2011.05.012 · DOI
  153. Chapman E , Berenstein EG , Dieguez M , et al . Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006;3:CD003880. · DOI
  154. 10.1016/j.lungcan.2013.11.004 · DOI
  155. 10.1136/thx.54.3.238 · doi:10.1136/thx.54.3.238
  156. 10.1016/j.ejca.2008.08.009 · DOI
  157. Taylor, 2013, Benefits of multidisciplinary teamwork in the management of breast cancer, Breast Cancer, 5, 79
  158. 10.1200/JOP.2014.003350 · DOI · Paper page
  159. 10.1038/bjc.2013.231 · DOI
  160. Bibby AC , Williams K , Smith S , et al . What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. BMJ Open 2016;6:e012092. · doi:10.1136/bmjopen-2016-012092
  161. Granieri, 2013, Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers, Neuropsychiatr Dis Treat, 9, 1193
  162. Arber, 2013, ’It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma, Psychooncology, 22, 1528, 10.1002/pon.3162 · DOI
  163. Clayson, 2005, Mesothelioma from the patient’s perspective, Hematol Oncol Clin North Am, 19, 1175, 10.1016/j.hoc.2005.09.003 · DOI
  164. Ball, 2016, A systematic literature review comparing the psychological care needs of patients with mesothelioma and advanced lung cancer, Eur J Oncol Nurs, 25, 62, 10.1016/j.ejon.2016.09.007 · DOI
  165. Moore, 2008, ’Hands of Time’: the experience of establishing a support group for people affected by mesothelioma, Eur J Cancer Care, 17, 585
  166. Chamming’s, 2013, Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme, Am J Ind Med, 56, 146, 10.1002/ajim.22106 · doi:10.1002/ajim.22106
  167. 10.1002/ajim.20705 · doi:10.1002/ajim.20705
  168. Kuschner, 2012, Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation, Am J Med Sci, 343, 206, 10.1097/MAJ.0b013e3182297912 · doi:10.1097/maj.0b013e3182297912
  169. 10.1016/j.ejrad.2009.02.002 · DOI
  170. 10.1097/JTO.0000000000000211 · doi:10.1097/jto.0000000000000211
  171. 10.1093/annonc/mdh059 · DOI · Paper page
  172. 10.1200/JCO.2006.06.8999 · DOI · Paper page
  173. 10.1183/09031936.00146110 · DOI
  174. Hilmi Ozden, 2007, Mustaffer Metintas Relationship between tumour size of MPM and its response to chemotherapy, Journal of Health Science, 53, 23, 10.1248/jhs.53.23 · doi:10.1248/jhs.53.23
  175. Nowak, 2005, CT, RECIST, and malignant pleural mesothelioma, Lung Cancer, 49, S37, 10.1016/j.lungcan.2005.03.030 · DOI
  176. 10.1007/s00330-008-0918-9 · DOI
  177. 10.1016/S0169-5002(03)00292-7 · DOI
  178. 10.1093/annonc/mdh059 · DOI · Paper page
  179. 10.1007/s00330-008-0918-9 · DOI
  180. 10.1097/00000478-200101000-00004 · DOI
  181. 10.1080/00313020802579250 · doi:10.1080/00313020802579250
  182. 10.1046/j.1365-2559.2003.01583.x · DOI
  183. Ordóñez, 2013, Mesothelioma with signet-ring cell features: report of 23 cases, Mod Pathol, 26, 370, 10.1038/modpathol.2012.172 · DOI
  184. 10.1309/QHCA-8594-TA7P-0DVQ · doi:10.1309/qhca-8594-ta7p-0dvq
  185. 10.1097/00000478-200604000-00006 · doi:10.1097/00000478-200604000-00006
  186. 10.1053/hupa.2001.24329 · doi:10.1053/hupa.2001.24329
  187. 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F · doi:10.1002/(sici)1096-9896(199910)189:2<251::aid-path412>3.0.co;2-f
  188. 10.1038/modpathol.3880018 · DOI · Paper page
  189. 10.1111/j.1365-2559.2009.03298.x · DOI
  190. 10.1309/XL6K-8E62-9FLD-V8Q8 · doi:10.1309/xl6k-8e62-9fld-v8q8
  191. 10.1002/cncr.22477 · DOI
  192. 10.1097/00000478-200302000-00002 · doi:10.1097/00000478-200302000-00002
  193. 10.1046/j.1365-2559.1998.00349.x · doi:10.1046/j.1365-2559.1998.00349.x
  194. 10.1038/modpathol.2009.180 · DOI
  195. Gotzos, 1996, The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type, Pathol Res Pract, 192, 137, 10.1016/S0344-0338(96)80208-1 · DOI
  196. Attanoos, 1996, Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma, Histopathology, 29, 209, 10.1111/j.1365-2559.1996.tb01393.x · doi:10.1111/j.1365-2559.1996.tb01393.x
  197. 10.1016/0046-8177(93)90080-Z · doi:10.1016/0046-8177(93)90080-z
  198. Collins, 1992, Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma, Am J Pathol, 141, 827
  199. Dejmek, 1997, Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma, APMIS, 105, 889, 10.1111/j.1699-0463.1997.tb05099.x · doi:10.1111/j.1699-0463.1997.tb05099.x
  200. 10.1002/dc.20202 · doi:10.1002/dc.20202

200 of 232 shown

Cited by

See all 221

Metadata

Authors
Woolhouse, I., Bishop, L., Darlison, L., De Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, D. A., Holmes, S., Kerr, K. M., Nakas, A., Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., & Maskell, N. A.
Venue
Thorax
Publisher
BMJ
Published
2018-02-14
Volume
73
Issue
Suppl 1
Pages
i1-i30
ISSN
  • 0040-6376 (ISSN-L)
  • 1468-3296
OpenAlex
W2789139181
Cited by
221
References
7
FWCI
19.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1136/thoraxjnl-2017-211321
The paper
Woolhouse, I., Bishop, L., Darlison, L., De Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, D. A., Holmes, S., Kerr, K. M., Nakas, A., Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., & Maskell, N. A. (2018). British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. https://doi.org/10.1136/thoraxjnl-2017-211321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.